New mRNA vaccine targets RSV in early human trial

NCT ID NCT07289503

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new mRNA vaccine called ABO1105 against respiratory syncytial virus (RSV). Around 96 healthy adults aged 18 and older will receive either the vaccine or a placebo. The main goal is to check if the vaccine is safe and triggers an immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ABO1105 (mRNA vaccine)

What this could lead to

If successful, this could lead to a safe and effective vaccine against RSV, a common respiratory virus.

What could go wrong

This is an early Phase 1 trial with only 96 participants, so safety and immune response are still unproven. The vaccine may not work or could cause side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Baise Center For Disease Control & Prevention

    Baise City, Baise, China